Publications | Research impact

Browse a collection of academic publications and research papers, contributed to by personnel from the Unit.

Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.

Anywaine, Z; HANSEN, C; Warimwe, GM; Abu-Baker Mustapher, G; Nyakarahuka, L; Balinandi, S; Ario, AR; Lutwama, JJ; ELLIOTT, A; KALEEBU, P;

2024

Virology journal, (2024).21 1 10.1186/s12985-024-02377-z.

The resurgent interest of anthropology in public health institutions.

HUTCHINSON, E; Bond, V; Enria, L; Palmer, J; Duclos, D; SEELEY, J; Calestani, M;

2024

(2024).

A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice.

Kitandwe, PK; Rogers, P; Hu, K; Nayebare, O; Blakney, AK; McKay, PF; KALEEBU, P; Shattock, RJ;

2024

Vaccines, (2024).12 10 10.3390/vaccines12101088.

Variability in body weight and morphology of Uganda's indigenous goat breeds across agroecological zones.

Nantongo, Z; Agaba, M; Shirima, G; Mugerwa, S; Opiyo, S; Mrode, R; BIRUNGI, J; Munishi, L;

2024

PloS one, (2024).19 1 10.1371/journal.pone.0296353.

Dimensions of vulnerability. Case 8.3: Studying the Impact of COVID-19 on Vulnerable Populations.

BANNINK MBAZZI, F; SEELEY, J; King, R;

2024

Research Ethics in Epidemics and Pandemics: A Casebook, , Springer Cham (2024).8, 10.1007/978-3-031-41804-4.

Experiences of community engagement for SARS-COV-2 and COVID-19 community surveillance in a rural and urban population in south western Uganda.

Bukenya, D; Mpairwe, B; Ssentongo, J; Ssenyomo, G; Fox, J; Newton, R; SEELEY, J; Joseph, M;

2024

African health sciences, (2024).24 3 10.4314/abs.v24i3.3.

Single-sample measured glomerular filtration rate in Malawi, South Africa, and Uganda.

Currin, S; George, JA; HANSEN, CH; Naicker, S; TOMLINSON, L; CRAMPIN, A; Kalyesubula, R; NEWTON, R; Nakanga, WP; NITSCH, D; Fabian, J;

2024

Kidney international, (2024).105 4 10.1016/j.kint.2024.01.020.

HLA-A*23 Is Associated With Lower Odds of Acute Retroviral Syndrome in Human Immunodeficiency Virus Type 1 Infection: A Multicenter Sub-Saharan African Study.

Lindquist, L; Kilembe, W; Karita, E; Price, MA; Kamali, A; KALEEBU, P; Tang, J; Allen, S; Hunter, E; Gilmour, J; Rowland-Jones, SL; Sanders, EJ; Hassan, AS; Esbjörnsson, J; Esbjörnsson, J;

2024

Open forum infectious diseases, (2024).11 4 10.1093/ofid/ofae129.

Victimisation in the life of persons with severe mental illness in Uganda: a pluralistic qualitative study.

Rutakumwa, R; Knizek, BL; Tusiime, C; Mpango, RS; Birungi, C; KINYANDA, E;

2024

BMC psychiatry, (2024).24 1 10.1186/s12888-024-05720-4.

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.

Serwanga, J; Oluka, GK; Baine, C; Ankunda, V; Sembera, J; Kato, L; Katende, JS; Odoch, G; Auma, BO; Gombe, B; COVID-19 Immunoprofiling Team,; Musenero, M; KALEEBU, P;

2024

PloS one, (2024).19 7 10.1371/journal.pone.0303113.